Novo Nordisk
NVO
#19
Rank
โ‚น40.339 T
Marketcap
โ‚น8,886
Share price
-1.49%
Change (1 day)
7.95%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

Novo Nordisk (NVO) - Total liabilities

Total liabilities on the balance sheet as of September 2024 : โ‚น3.500 Trillion

According to Novo Nordisk's latest financial reports the company's total liabilities are โ‚น3.500 Trillion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Novo Nordisk - Total liabilities on balance sheet (from 2001 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31โ‚น2.563 T36.35%
2022-12-31โ‚น1.880 T34.06%
2021-12-31โ‚น1.402 T42.18%
2020-12-31โ‚น986.42 B35.64%
2019-12-31โ‚น727.25 B15.2%
2018-12-31โ‚น631.31 B16.73%
2017-12-31โ‚น540.82 B7.54%
2016-12-31โ‚น502.92 B15.19%
2015-12-31โ‚น436.58 B14.71%
2014-12-31โ‚น380.60 B19.83%
2013-12-31โ‚น317.61 B30.67%
2012-12-31โ‚น243.07 B-3.21%
2011-12-31โ‚น251.12 B28.5%
2010-12-31โ‚น195.42 B15.02%
2009-12-31โ‚น169.90 B6.54%
2008-12-31โ‚น159.47 B33.34%
2007-12-31โ‚น119.59 B4.54%
2006-12-31โ‚น114.40 B12.25%
2005-12-31โ‚น101.91 B17.43%
2004-12-31โ‚น86.79 B22.58%
2003-12-31โ‚น70.80 B20%
2002-12-31โ‚น58.99 B-2.77%
2001-12-31โ‚น60.68 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
โ‚น10.708 T 205.95%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น5.171 T 47.74%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น6.452 T 84.34%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น5.133 T 46.67%๐Ÿ‡ซ๐Ÿ‡ท France